Coeptis Therapeutics Holdings, Inc.
$15.54
▲
6.21%
2026-04-21 06:09:01
coeptistx.com
NCM: COEP
Explore Coeptis Therapeutics Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$91.17 M
Current Price
$15.54
52W High / Low
$21.41 / $6.26
Stock P/E
—
Book Value
$2.36
Dividend Yield
—
ROCE
-90.67%
ROE
-1.37%
Face Value
—
EPS
$-2.81
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
-0.43
Debt / Equity
1.91
Current Ratio
4.16
Quick Ratio
4.16
Forward P/E
-70.29
Price / Sales
54.56
Enterprise Value
$68.79 M
EV / EBITDA
-5.8
EV / Revenue
50.47
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | PMV Pharmaceuticals, Inc. | $1.43 | — | $73.59 M | — | -81.99% | -55.37% | $1.88 / $0.81 | $1.96 |
| 2. | Cellectar Biosciences, Inc. | $2.95 | — | $12.21 M | — | -224.66% | -1.7% | $20.7 / $2.43 | $1.89 |
| 3. | Crinetics Pharmaceuticals, Inc. | $40.25 | — | $4.21 B | — | -49.63% | -40.17% | $57.99 / $25.83 | $10.38 |
| 4. | Terns Pharmaceuticals, Inc. | $52.74 | — | $6.09 B | — | -10.92% | -14.23% | $53.19 / $2.23 | $8.96 |
| 5. | ImageneBio, Inc. | $6 | — | $65.99 M | — | -34.18% | -68.91% | $18 / $3.94 | $11.91 |
| 6. | MoonLake Immunotherapeutics | $17.89 | — | $1.32 B | — | -64.61% | -60.78% | $62.75 / $5.95 | $4.27 |
| 7. | Cullinan Therapeutics, Inc. | $14.52 | — | $911.52 M | — | -58.85% | -44.02% | $16.74 / $5.68 | $6.79 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.86 M | 0.24 M | 0.2 M | 0.06 M | 0 M | — |
| Operating Profit | -1.99 M | -2.48 M | -4.52 M | -4.06 M | -2.16 M | — |
| Net Profit | -1.58 M | -2.74 M | -3.53 M | -3.06 M | -1.95 M | — |
| EPS in Rs | -0.25 | -0.44 | -0.57 | -0.49 | -0.31 | -1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.36 M | 0 M | 0 M | 0 M |
| Operating Profit | -13.04 M | -10.05 M | -21.49 M | -34.2 M |
| Net Profit | -11.92 M | -10.68 M | -21.27 M | -37.57 M |
| EPS in Rs | -1.91 | -1.72 | -3.42 | -6.04 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 16.15 M | 8.91 M | 4.57 M | 7.92 M |
| Total Liabilities | 2.09 M | 5.04 M | 3.76 M | 3.46 M |
| Equity | 13.56 M | 3.38 M | 0.81 M | 4.45 M |
| Current Assets | 7.35 M | 1.05 M | 1.75 M | 3.94 M |
| Current Liabilities | 1.77 M | 4.51 M | 2.99 M | 2.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.6 M | -6.65 M | -7.24 M | -3.88 M |
| Investing CF | 0 M | 0 M | 0 M | 0 M |
| Financing CF | 13.74 M | 5.71 M | 4.92 M | 5.49 M |
| Free CF | -8.6 M | -6.65 M | -7.24 M | -3.88 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 49.78% | 43.4% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-12-31 | 1:0.05 |